Biodesix (NASDAQ:BDSX) Director Jack Schuler Buys 13,900 Shares of Stock

Biodesix, Inc. (NASDAQ:BDSX) Director Jack Schuler acquired 13,900 shares of Biodesix stock in a transaction dated Monday, August 10th. The stock was purchased at an average cost of $24.25 per share, for a total transaction of $337,075.00. Following the completion of the purchase, the director directly owned 527,110 shares in the company, valued at approximately $12,782,417.50. This represents a 2.71% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through this link.

Biodesix Trading Down 0.4%

Shares of BDSX stock opened at $24.22 on Thursday. The company has a quick ratio of 2.85, a current ratio of 2.85 and a debt-to-equity ratio of 5.12. Biodesix, Inc. has a fifty-two week low of $5.26 and a fifty-two week high of $25.52. The firm’s 50 day moving average price is $20.19 and its two-hundred day moving average price is $16.05. The stock has a market cap of $255.52 million, a price-to-earnings ratio of -7.64 and a beta of 0.56.

Biodesix (NASDAQ:BDSX) last released its quarterly earnings data on Wednesday, August 5th. The company reported ($0.71) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.90) by $0.19. Biodesix had a negative net margin of 26.97% and a negative return on equity of 788.19%. The company had revenue of $26.86 million during the quarter, compared to analyst estimates of $26.03 million. On average, analysts anticipate that Biodesix, Inc. will post -2.68 EPS for the current year.

Analyst Upgrades and Downgrades

A number of brokerages have commented on BDSX. Canaccord Genuity Group boosted their price objective on Biodesix from $27.00 to $35.00 and gave the stock a “buy” rating in a research note on Monday. HC Wainwright reiterated a “buy” rating and set a $27.00 target price (up from $26.00) on shares of Biodesix in a report on Thursday, August 6th. Weiss Ratings upgraded Biodesix from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, June 12th. Finally, Roth Capital began coverage on shares of Biodesix in a research report on Wednesday, June 24th. They issued a “buy” rating and a $32.00 price objective for the company. One analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $31.33.

Institutional Investors Weigh In On Biodesix

Hedge funds and other institutional investors have recently bought and sold shares of the business. XTX Topco Ltd boosted its stake in shares of Biodesix by 99.4% during the 2nd quarter. XTX Topco Ltd now owns 205,647 shares of the company’s stock valued at $58,000 after buying an additional 102,494 shares during the last quarter. Cetera Investment Advisers bought a new position in Biodesix during the 4th quarter valued at $68,000. DRW Securities LLC acquired a new position in Biodesix during the 4th quarter worth $105,000. Allworth Financial LP bought a new stake in shares of Biodesix in the 2nd quarter worth about $112,000. Finally, Millennium Management LLC acquired a new stake in shares of Biodesix in the 3rd quarter valued at about $113,000. 20.96% of the stock is currently owned by hedge funds and other institutional investors.

About Biodesix

Biodesix, Inc is a commercial-stage molecular diagnostics company headquartered in Boulder, Colorado, that develops and delivers blood-based tests to improve the diagnosis and management of lung diseases, including lung cancer. The company integrates advanced proteomic and, more recently, genomic technologies to offer noninvasive testing solutions designed to guide clinical decision-making. Biodesix operates a CLIA-certified and CAP-accredited laboratory, allowing it to process patient samples at scale and maintain rigorous quality standards.

The company’s flagship product, VeriStrat®, is a proteomic test that stratifies patients with non-small cell lung cancer into groups more likely to benefit from specific therapies.